DEDICATED TO DEVELOPING INNOVATIVE
SMALL MOLECULE ORAL THERAPIES FOR
IMMUNE-MEDIATED INFLAMMATORY DISEASES
Using Artificial Intelligence and Machine Learning
to Decode the Mechanisms that Drive Inflammation
Welcome to Invea Therapeutics, or Invea. We are a biotechnology company dedicated to advancing the treatment of immune-mediated inflammatory diseases, or IMIDs. Our mission is to transform the lives of patients with chronic IMIDs through the development of oral, safe and effective small molecule product candidates.
DEDICATED TO DEVELOPING INNOVATIVE SMALL MOLECULE ORAL THERAPIES FOR IMMUNE-MEDIATED INFLAMMATORY DISEASES
Using artificial intelligence and machine learning to Decode the Mechanisms that Drive Inflammation
Welcome to Invea Therapeutics or Invea. We are a biotechnology company dedicated to advancing the treatment of immune-mediated inflammatory diseases (IMIDs). Our mission is to transform the lives of patients with chronic IMIDs through the development of oral, safe and effective small molecule product candidates.
Developing Small Molecule Oral Therapeutics for IMIDs
At Invea, we are working to bring effective solutions to patients suffering from immune-mediated inflammatory diseases (IMIDs). Our journey is driven by a deep understanding of the complexity of these conditions and a passion to make a difference.
Knowledge is the Key to Progress
We believe that knowledge is the key to progress. Our unique approach combines the power of artificial intelligence (AI) and machine learning (ML) with the expertise of our dedicated team’s extensive experience and expertise. Together, we decode the intricate mechanisms driving IMIDs, unlocking potential new avenues for treatment.
Solving a Complex Puzzle by Collecting the Pieces
IMIDs are a complex puzzle, but we are collecting the pieces to solve it. Our commitment to scientific excellence drives us to explore the depths of inflammation starting with mast cell and inflammasome biology, two key players in IMID pathogenesis. By targeting these critical pathways, we aim to address common and rare IMIDS.
Accelerating Breakthroughs in Treatment
We believe our lead program, INVA8001, and early-stage program INVA8003, hold the potential to reshape the landscape of IMID treatment. With rigorous research and development, we are on a journey to deliver hope to those who need it most.
We'd Love to Hear from You
As we embark on this mission to revolutionize the treatment of chronic inflammation, we invite you to stay connected with us. Explore our website to learn more about our groundbreaking research, innovative approach, and the potential we hold to unlock a brighter future for patients suffering from immune-mediated inflammatory disorders.
